(Finance) – Amgen announced that he had completed the acquisition Of Horizon Therapeutics for a total amount of approximately 27.8 billion dollarsequal to a value of 116.50 dollars per share, after receiving the green light from the US Federal Trade Commission last month.
“This is an important moment for us as we welcome Horizon employees to Amgen and begin working together to respond to the urgent needs of patients suffering from serious illnesses,” said CEO Robert A. Bradway. “With the integration of Horizon, we are providing a new impetus to our core business and we further strengthen Amgen’s leadership across a broader range of therapeutic areas.”
From a strategic and financial point of view, the acquisition will bring significant consequences including an increase in cash flows which will allow the strengthening of investments in innovation, strengthening the company’s financial structure and access to the capital market; and an increase in turnover: Amgen expects a positive impact on earnings per share starting from 2024.
Amgen expects to update its forecast for 2023 at the time of its announcements third quarter resultswe read in a note.